




PATENT
Docket No. 300622004620

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EV 143875738 US

Date of Deposit: October 22, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Box Sequence, Assistant Commissioner for Patents, Washington, D.C. 20231.


Diane Blevins

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Rajesh GOKHALE et al.

Serial No.: 10/091,244

Filing Date: 04 March 2002

For: METHODS TO MEDIATE
POLYKETIDE SYNTHASE MODULE
EFFECTIVENESS

Examiner: To be assigned

Group Art Unit: 1652

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES**

Box Sequence
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This is in response to the Notice to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures, mailed August 22, 2002, for which a response is due on October 22, 2002. Accordingly, this response is timely filed.

Please enter the following substitute Sequence Listing, CRF and remarks:

In the Sequence Listing:

Please replace the paper copy and the computer-readable form (CRF) copy of the Sequence Listing submitted for this application, on July 24, 2002, with the substitute sheets of the sequence listing, pages 1-7, and the CRF copy submitted herewith.

REMARKS


Applicants have identified the genetic source of the artificial sequence of SEQ ID NO: 20 as the N-terminal linker of M3, meeting the requirements of the Raw Sequence Error Summary in the above matter, and have corrected the paper copy and the CRF accordingly. Support for this Amendment therefore can be found, for example, at page 31, lines 24-25 of the specification as filed. Enclosed are the substitute sheets of the sequence listing, pages 1-7, and the substitute CRF copy of the sequence listing, with the requested "Feature" added to SEQ ID NO: 20. The substitute sheets of the sequence listing and the CRF copy submitted herewith, in accordance with 37 C.F.R. § 1.825(a) and (b), respectively, are the same and contain no new matter. Accordingly, entry of the paper copy and the CRF copy of the Sequence Listing into the above-captioned case is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 300622004620. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: October 22, 2002

By:


Brenda J. Wallach
Registration No. (45,193)

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-7961
Facsimile: (858) 720-5125